Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Asthma & COPD Therapies Market 2017-2027

Visiongain Ltd
Posted on: 14 Sep 17
Global Asthma & COPD Therapies Market 2017-2027

PR Newswire

LONDON, September 14, 2017

LONDON, September 14, 2017 /PRNewswire/ --

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 300-page report you will receive 113 tables and 130 figures - all unavailable elsewhere.

The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope: 

• Global Asthma & COPD Therapies Market forecasts  from 2017-2027, further broken down into:
Global Asthma Therapies Market forecasts
Global COPD Therapies Market forecasts

• Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
- Bronchodilators monotherapy
- Anti-inflammatory drugs
- Combination drugs

• Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

• Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
Anti-leukotrienes: Singulair
Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

• Revenue forecast for the Combination drugs market and the leading drugs:
- Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:
- The US
- Japan
- EU5: Germany, France, UK, Italy, Spain
- BRIC: Brazil, Russia, India, China
- Mexico
- Other Countries

• This report discusses the leading companies in the global asthma & COPD therapies market:
- GSK
- Boehringer Ingelheim
- AstraZeneca
- Novartis
- Merck
- Roche
- Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter's five forces analysis of the global asthma & COPD therapies market.

Visiongain's study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Global Asthma & COPD Therapies Market 2017-2027:
Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100.

Or click on https://www.visiongain.com/Report/1988/Global-Asthma-COPD-Therapies-Market-2017-2027

Companies Mentioned in the Report 

3M Drug Delivery Systems

AB Science

Actavis

Alcon

Alembic

Allen and Hanburys

Allergan

Almirall

Apotex

Ario Pharma

Array BioPharma

Aspen Pharmacare

Astellas Pharma

AstraZeneca

Aurobindo Pharma

Bellephron

Ben Vue Laboratories

BioWa

BioXpress Therapeutics

Boehringer Ingelheim

Breath Limited

Bristol-Meyer Squibbs

Catalent Pharma Solutions

Cephalon

Ception Therapeutics

Chiesi Pharmaceuticals

Ciba-Geigy

Cipla

Circassia Pharmaceuticals

CVS Caremark

Daewoong Pharmaceutical

Dainippon Sumimoto

Dr. Reddy's Laboratories

Express Scripts

Forest Pharmaceuticals

Fountain Biopharma

Genentech (Roche)

Grifols

GSK

Hikma Pharmaceuticals

Ikaria

Invion

Kamada

Kyorin Pharmaceuticals

Kyowa Hakko Kirin

Lilly

Mariposa

MedicNova

Medimmune

Menarini

Merck & Co.

Mylan

Novartis

Nycomed

Omega Pharma

Orion Pharmaceuticals

Pearl Therapeutics

Perrigo

Pfizer

Prosonix

Reckitt Becnkiser

Regeneron

Roche

Roxane Laboratories

Sandoz (Novaris)

Sanofi

Schering-Plough's

SkyePharma

Sofotec

Stempeutics

Sunovion Pharmaceuticals

Synairgen

Takeda Pharmaceuticals

Tanox

Teva

Theravance

Vectura

Viatris

Watson (Actavis)

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain Ltd

PR Newswire
www.prnewswire.com

Last updated on: 14/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.